BD (Becton, Dickinson and Company) announced strong financial results for its fiscal 2025 first quarter, which ended December 31, 2024. The company reported total revenues of $5.168 billion, a 9.8% increase as reported and 3.9% organic growth year-over-year, exceeding expectations.
Adjusted diluted earnings per share for Q1 FY25 were $3.43, representing a 28.0% increase from the prior-year period, also ahead of expectations. This performance was driven by strong operational execution across segments, with BD Medical organic revenue growth led by Medication Delivery Solutions and Medication Management Solutions.
Concurrently, BD's Board of Directors unanimously authorized management to pursue a plan to separate the Biosciences and Diagnostic Solutions business from the rest of BD. This strategic move aims to enhance strategic focus, drive growth-oriented investments, and unlock significant value for shareholders by creating two focused entities: 'New BD' as a pure-play MedTech company and a pure-play Life Sciences Tools & Diagnostics leader.
The company updated its fiscal 2025 guidance, increasing Adjusted Diluted EPS to a range of $14.30 to $14.60, reflecting 10% growth at the midpoint. While GAAP revenues were adjusted to $21.7 billion to $21.9 billion, organic revenue growth guidance was maintained at 4.0% to 4.5%, demonstrating confidence in the full-year outlook despite incremental translational foreign currency impacts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.